BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30293231)

  • 1. Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.
    Gómez-Caamaño A; González-San Segundo C; Henríquez I; Maldonado X; Zapatero A;
    Clin Transl Oncol; 2019 Apr; 21(4):420-432. PubMed ID: 30293231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Consensus on castration-resistant prostate cancer management in Spain.].
    Alcaraz A; Martínez-Piñeiro L; Rodríguez A; Rubio J; Borque Á; Burgos J; Carballido J; Cózar JM; Crespo I; Esquena S; Gómez-Veiga F; López D; Miñana B; Morote J; Ribal MJ; Solsona E; Suárez JF; Unda M
    Arch Esp Urol; 2017 Nov; 70(9):777-791. PubMed ID: 29099380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
    Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
    Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities.
    Maluf F; Soares A; Avanço G; Hada AL; Cardoso APG; Carneiro A; Herchenhorn D; Jardim DLF; Schutz FA; Kater FR; Pereira FMT; Monteiro FSM; Morbeck IAP; Reolon JFN; da Trindade KM; Andrade LMQDS; Nogueira LM; Furoni R; Natel RA; Dos Reis RB; Fogace RN; Souza VC
    Int Braz J Urol; 2021; 47(2):359-373. PubMed ID: 33284538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method.
    Terrone C; Berruti A; Papotti M; Vavassori V; Sciarra A
    Tumori; 2016 Oct; 102(5):514-520. PubMed ID: 26166221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
    Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney CJ; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ekeke ON; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis C; Mahal B; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro CJ; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
    Eur J Cancer; 2023 May; 185():178-215. PubMed ID: 37003085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
    Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney C; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ngozi Ekeke O; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis CJ; Mahal BA; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Pablo Sade J; Sartor OA; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
    Eur Urol; 2023 Mar; 83(3):267-293. PubMed ID: 36494221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
    Anantharaman A; Small EJ
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
    Shore ND; Drake CG; Lin DW; Ryan CJ; Stratton KL; Dunshee C; Karsh LI; Kaul S; Kernen K; Pieczonka C; Sieber P; Stewart C; Williams M; Concepcion RS
    Prostate; 2020 Oct; 80(14):1159-1176. PubMed ID: 32779781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
    Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
    Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.
    López Torrecilla J; Hervás A; Zapatero A; Gómez Caamaño A; Macías V; Herruzo I; Maldonado X; Gómez Iturriaga A; Casas F; González San Segundo C
    Rep Pract Oncol Radiother; 2015; 20(4):259-72. PubMed ID: 26109913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
    Climent MÁ; León-Mateos L; González Del Alba A; Pérez-Valderrama B; Méndez-Vidal MJ; Mellado B; Arranz JÁ; Sánchez-Hernández A; Cassinello J; Olmos D; Carles J
    Crit Rev Oncol Hematol; 2015 Nov; 96(2):308-18. PubMed ID: 26100652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality indicators in radiation oncology: proposal of the Spanish Society of Radiation Oncology (SEOR) for a continuous improvement of the quality of care in oncology.
    López Torrecilla J; Marín I Borràs S; Ruiz-Alonso A; Jaen Olasolo J; Vázquez de la Torre ML; Bóveda Carro E; Rodríguez A; Ignacio García E; Caballero Martínez F; Campos Lucas FJ; Lara Jiménez PC; Martínez JC; Ferrer Albiach C
    Clin Transl Oncol; 2019 Apr; 21(4):519-533. PubMed ID: 30311145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recomendations on the management of controversies in advanced castrate-resistant prostate cancer].
    Cózar JM; Solsona E; Morote J; Miñana B; Maroto JP; González Del Alba A; Climent MA; Carles J; Alcaraz A; Castellano D; ; ;
    Actas Urol Esp; 2012; 36(10):569-77. PubMed ID: 22999347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG.
    Henríquez I; Rodríguez-Antolín A; Cassinello J; Gonzalez San Segundo C; Unda M; Gallardo E; López-Torrecilla J; Juarez A; Arranz J
    Clin Transl Oncol; 2018 Mar; 20(3):392-401. PubMed ID: 28785912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
    Gillessen S; Attard G; Beer TM; Beltran H; Bjartell A; Bossi A; Briganti A; Bristow RG; Chi KN; Clarke N; Davis ID; de Bono J; Drake CG; Duran I; Eeles R; Efstathiou E; Evans CP; Fanti S; Feng FY; Fizazi K; Frydenberg M; Gleave M; Halabi S; Heidenreich A; Heinrich D; Higano CTS; Hofman MS; Hussain M; James N; Kanesvaran R; Kantoff P; Khauli RB; Leibowitz R; Logothetis C; Maluf F; Millman R; Morgans AK; Morris MJ; Mottet N; Mrabti H; Murphy DG; Murthy V; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Reiter RE; Roach M; Rubin M; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Shore N; Small E; Smith M; Soule H; Sternberg CN; Steuber T; Suzuki H; Sweeney C; Sydes MR; Taplin ME; Tombal B; Türkeri L; van Oort I; Zapatero A; Omlin A
    Eur Urol; 2020 Apr; 77(4):508-547. PubMed ID: 32001144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation and diagnosis for castration resistant prostate cancer: CRPC].
    Kamoto T
    Nihon Rinsho; 2014 Dec; 72(12):2103-7. PubMed ID: 25518341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
    Benidir T; Hersey K; Finelli A; Hamilton R; Joshua AM; Kulkarni G; Zlotta A; Fleshner N
    Urol Oncol; 2018 May; 36(5):240.e13-240.e20. PubMed ID: 29454590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
    Virgo KS; Basch E; Loblaw DA; Oliver TK; Rumble RB; Carducci MA; Nordquist L; Taplin ME; Winquist E; Singer EA
    J Clin Oncol; 2017 Jun; 35(17):1952-1964. PubMed ID: 28441112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.